



PERSONAIZED HEALTH + FUNCTIONAL WELLNESS

COMPANY:

Co-founders are bringing together AF Life Sciences and BodySync Genetics under the umbrella of MySci™ to deliver their third major consumer healthcare success. BodySync founders helped Lorimar bring its iconic celebrity personal home fitness movement (including **Jane Fonda**) to the masses. They also worked with infomercial giant Guthy-Renker to usher in the Pilates workout to the mainstream, including the **Winsor Pilates** workout franchise. Now they're teaming up with AF Life Sciences to bring its diversified portfolio of personalized and functional life sciences products to consumers – beginning with North America.

BODYSYNC GENOMICS TECHNOLOGY/INNOVATION PLATFORM:

BodySync's product line includes at-home **DNA test kits with sterile cheek swabs**, links to online surveys and access to online **Health Action Plans** that identify **precision nutrient needs** for each individual. These tests are developed and processed to CLIA lab certification standards.

AF LIFE SCIENCES TECHNOLOGY/INNOVATION PLATFORM:

AFLS' CBD, mushroom supplements, and topical products are manufactured internally to exacting CDPHE GMP certification standards. AFLS' **nanotechnology** delivers maximum nutrient absorption to take full advantage of the **precision micronutrient recommendations generated by BodySync's health action plans**.

FULL PIPELINE/MARKET READY:

AFLS has **multiple contracts pending** for major national pharmacy chain distribution of its **CBD and mushroom products in Mexico**. Its Upstart Kombucha products are gaining traction with **major natural grocers** in America. BodySync lab developed DNA testing technology has been **federally validated** by CMS for more than a decade and will be integrated into MySci operations.

VALUATION MULTIPLES:

MySci is projecting to be on a \$10M annual revenue path by Q1-end 2023. By integrating functional wellness with genomic health care technology – MySci future valuation on multiples of revenue associated with genomics and advanced life sciences companies – ranging from **10x to 20x revenue (Finerva)**.

REVENUE PROJECTIONS:

Management Case: (Raise/deploy \$27.5M): Y3 REVENUE, 338M

OFFERING:

Stage: Consumer product launch

Seeking: \$2.5M Immediate (plus growth capital of \$25M)

Immediate Offering: **Convertible Preferred or Equity Stake**

Combined Enterprise Value: TBD and Triggered Upon Public Offering

Combined Company Hard and IP Assets: \$23M

Exit Strategy: Go public via CPC on TSX Ventures Exchange

CONTACT:

Vince Pavelock, CEO (323-499-1770) | vpavelock@mysci.net

Troy Daniels, President (303-882-8920) | tdaniels@mysci.net

